Related Experiment Video

Updated: May 15, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Glucose and LDL lowering: the need for intensive therapy

Stefano Del Prato1

  • 1Department of Clinical and Experimental Medicine, Section of Metabolic Diseases and Diabetes, University of Pisa, Italy. stefano.delprato@med.unipi.it

Current Vascular Pharmacology
|December 25, 2012
PubMed

Insights

Intensive glucose lowering in diabetes effectively reduces microvascular complications but has uncertain effects on macrovascular issues. Multifactorial interventions, including glucose and lipid management, are crucial for diabetic patients.

Area of Science:

  • Endocrinology
  • Cardiology
  • Diabetology

Background:

  • Hyperglycemia strongly correlates with micro- and macrovascular complications in diabetes.
  • Intensive glucose lowering reduces microvascular risks (retinopathy, nephropathy, neuropathy) but its macrovascular impact is debated.

Purpose of the Study:

  • To analyze the impact of intensive glucose lowering on diabetic complications.
  • To explore reasons for the uncertain effect on macrovascular complications.
  • To emphasize the need for multifactorial interventions in diabetes management.

Main Methods:

  • Review of epidemiological analyses and clinical trial data.
  • Analysis of factors influencing outcomes in intensive diabetes treatment.
  • Consideration of data from multi-intervention studies like Steno-2.

Main Results:

  • Intensive glycemic control effectively prevents microvascular complications.
  • The effect of intensive glucose lowering on macrovascular complications remains uncertain.
  • Diabetic patients often have high cardiovascular risk, potentially leading to aggressive baseline treatment of risk factors.

Conclusions:

  • Multifactorial intensive treatment is essential for diabetic patients.
  • Combined glucose and lipid lowering strategies are recommended.
  • Addressing multiple cardiovascular risk factors is critical for improving outcomes in diabetes.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...